You’re Looking at a Cancer Breakthrough That Could Change the Game

We just dug through fresh trial data, and this one’s different. A lightning-fast Phase 3 launch signals a shot at rewriting the playbook in one of medicine’s toughest battles, and you need to know about it.

The escalating trade tensions are reshaping the AI market.

With Washington tightening export restrictions on advanced AI chips to China, giants like Nvidia face steep revenue losses.

This disruption creates a rare opening for U.S.-based AI innovators, and I’ve pinpointed 9 under-the-radar companies with:

Get all 9 tickers, financials, and growth forecasts in my free report: “Top 9 AI Stocks for This Month.”

Markets are moving fast—catch these plays before the crowd.

[Download Free Now]

Stock futures are climbing ahead of the open, but everyone’s waiting on inflation data this morning to bring the heat, one way or another.

Elite Trade Club now offers text alerts — so you get trending stocks and market-moving news sent straight to your phone before the bell.

Email’s great. Texts are faster.

👉 Click here to get our pre-market report to your cell for free!

You’ll be first in line when the market starts moving.

Premarket Earnings:

Aftermarket Earnings:

Economic Reports:

Opendoor has gone from eviction notice to housewarming invites. Just a few months back, the stock was trading under a buck and staring down delisting. Fast-forward to today: Shopify’s ex-COO Kaz Nejatian is now running the show, founders Keith Rabois and Eric Wu are back in the boardroom, and investors are acting like this place just got a full HGTV makeover.

Shares pumped up 30% after hours, premarket looks lively, and suddenly everyone’s wondering if this is the next Carvana-style comeback.

The new playbook is “founder mode + AI everywhere.” Expect algorithms handling pricing, underwriting, and maybe even staging your living room. Add in $40M of fresh capital, and Opendoor isn’t just squatting; it’s got cash for renovations. Social media traders are fueling the hype, calling it Zillow-meets-Carvana with meme-stock steroids.

Why it Matters: You’re looking at a complete narrative flip. From penny stock pariah to retail darling in weeks, Opendoor is proving that housing disruption isn’t dead; it just needed a new landlord.

Investor Takeaway: You’ll see opportunity if you like trading volatility dressed up as growth. Short-term, this is all about riding hype cycles and breakout setups. Long-term, you need proof they can actually flip homes profitably in a high-rate market. Until then, treat this like an Airbnb stay, fun for now, but maybe not your forever home.

Trevi Therapeutics is turning heads, and maybe curing coughs. Its lead drug, Haduvio, is being developed for chronic cough, a condition that sounds niche but affects millions and has almost no good treatments.

Morgan Stanley clearly liked the pitch, slapping an $18 target and calling TRVI a potential multibagger. Investors coughed politely in response and pushed shares toward fresh highs.

Here’s the kicker. Existing therapies for chronic cough are either weak sauce or come with baggage like abuse risk. Haduvio could offer clean efficacy without the side effects, which is why the Street sees billion-dollar potential. Big Pharma already sniffed around, with GSK and Merck having written billion-dollar checks in this exact space. If the little guy Trevi nails its trials, don’t be shocked if it becomes buyout bait.

Why it Matters: You’ve got a small-cap biotech with a giant addressable market. Chronic cough isn’t sexy, but it’s lucrative, and demand is strong. That’s the kind of mismatch investors love.

Investor Takeaway: You’ll see an opportunity if you like asymmetric bets. A green light from trials could send this stock soaring and maybe even land a Big Pharma partner. The risk is that if Haduvio flops, your money goes down the wrong pipe. Handle position sizing like you would cough syrup. Measured, careful, and don’t overdo it.

The Fed is uncertain.

The Trade War is rattling markets.

Retail investors are panicking, but smart money is moving in.

They’re quietly loading up on 3 consumer defensive plays:

This isn’t speculation - it’s the only survival strategy in today’s market.

Get all 3 tickers, growth catalysts, and buy zones in my free report: “3 Defensive Stocks to Own Now.”

Claim your FREE copy now before it gets paywalled.

Revolution Medicines is trying to rewrite the playbook for one of the deadliest cancers out there. Its RAS(ON) inhibitor, daraxonrasib, just dropped new data showing strong response rates in pancreatic cancer, both as monotherapy and combined with chemo.

For patients facing a brutal diagnosis, that’s potentially life-extending. For investors, it’s the kind of late-stage data that can move a stock from “maybe” to “must-watch.”

The company is wasting no time, lining up a Phase 3 trial (RASolute 303) for Q4. That’s a lightning-fast move and a signal that they see blockbuster potential. Remember, over 90% of pancreatic cancers have RAS mutations, so if daraxonrasib works, it’s addressing the majority of patients, not just a small slice.

Why it Matters: This is the kind of pivot point biotech investors live for. Success here could establish daraxonrasib as a backbone therapy and vault Revolution into the upper tier of oncology names. With other RAS inhibitors in its pipeline, there are multiple shots on goal.

Investor Takeaway: You’ll see opportunity if you’ve got patience and nerves of steel. Every data drop will be a market mover, and volatility will be part of the package. But if Revolution sticks the landing in Phase 3, the upside runway is huge. Until then, consider this a long-haul flight: buckle in, expect turbulence, and know the destination could be worth it.

Yesterday’s beatdown was brutal, down 35% on weak IP and China jitters. Today’s bounce looks more like “we might’ve overcooked the selloff” than real conviction. Core EDA is still humming, the backlog grew, and Ansys adds some cushion. But confidence took a hit, and rerates like this don’t heal overnight.

Biotech giveth, biotech taketh away. Avidity launched a $500M offering and the market hit “sell first, read prospectus later.” The science (muscle-targeted RNA drugs) hasn’t changed, but dilution math always stings. Raise cash, build runway, grow pipeline—that’s the drill.

Battery hopeful Enovix is tapping the convert market with $300M in notes. That means dilution jitters now, maybe M&A or growth fuel later. Capped calls soften the blow, but hedging flows can whack the stock near-term. The story is still about execution, customers, and scale, not convert math.

Most portfolios deliver “average.”

But if you’re reading this, you’re not after average.

That’s why our team just unveiled 5 carefully selected stocks with the potential to deliver massive upside.

What sets them apart?

Past reports from this series have highlighted stocks that posted gains of +175%, +498%, and even +673%.

Now, it’s your chance to see the latest 5 picks—completely free.

[Click here to claim your copy before midnight tonight]

Extraordinary opportunities don’t come often. Don’t miss this one.

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.